hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 16:23:54 - browse：348

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： The biotech scorecard for Q3: 15 stock

WSS

Readout Newsletter: Illumina, CRISPR, Regeneron

Cancer, immunology, HIV research ensnared in fetal tissue politics

'Patient friction coefficient' can gauge a clinical trial's patient burden

Canadians with cystic fibrosis outlive Americans by a decade

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Skip the lead apron during X

Wikipedia

hotspot

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Vertex cell therapy lets patients with type 1 diabetes stop insulin

In Memoriam: Notable people who died in 2023

Mirador, a new biotech startup, launches with $400 million

Sports medicine is finally prioritizing gender equality

'Screen and refer' systems are hurting patients

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

A letter from the executive editor: The 2023 STATUS List

Medical leaders decry Supreme Court decision on affirmative action

Pfizer, Moderna say biotech, pharma drug development is a sprint

focus

'Patient friction coefficient' can gauge a clinical trial's patient burden

What Kate Middleton's cancer revelation might teach the world

A letter from the executive editor: The 2023 STATUS List

Mirador, a new biotech startup, launches with $400 million

With Wegovy coverage, Medicare patients may face high costs

Erich Jarvis studies song birds to learn about human stuttering

entertainment

hotspot

hotspot

knowledge